Repaglinide.
Level 5 - mechanism / opinion, no new human data
Narrative review and drug profile with no systematic review methodology described
PubMed 9739505 · doi:10.2165/00002512-199813020-00008
What was done
This paper reviews pharmacokinetic, preclinical, and comparative clinical trial data for repaglinide, a novel non-sulfonylurea insulin secretagogue for type 2 diabetes mellitus. It evaluates repaglinide dosed at 0.5 to 4 mg two to three times daily before meals as monotherapy compared with glibenclamide (2.5 to 15 mg/day), as well as in combination with metformin.
What was found
The abstract reports no numerical values, sample sizes, or statistical metrics. Qualitatively, repaglinide reduced fasting and postprandial blood glucose across animal models, healthy volunteers, and patients with type 2 diabetes. It demonstrated glycemic control similar to glibenclamide, enhanced control when combined with metformin, and was reported to allow missed meals without apparently increasing hypoglycemia risk compared with glibenclamide.
Why it matters
Repaglinide offers a rapid-acting, non-renally excreted secretagogue option that allows preprandial dosing tailored to individual meal schedules in type 2 diabetes.
Limits
The abstract provides no quantitative data, effect sizes, trial durations, patient demographics, or adverse event rates. As a narrative review, it lacks systematic search criteria and formal quality assessment of the underlying trials.
Cited by
- supports Repaglinide functions by stimulating the release of insulin from pancreatic beta cells.